Orphagen Pharmaceuticals

Orphagen Pharmaceuticals, founded in 2001 and based in San Diego, is a private, preclinical-stage biotech focused on drug discovery for orphan nuclear receptors. The company has built a platform for screening ligands to modulate these receptors, leading to a pipeline with programs in oncology (including adrenal and squamous cancers) and inflammatory bowel disease (ulcerative colitis and Crohn's disease). As a pre-revenue entity, Orphagen's strategy involves internal R&D to generate first-in-class drug candidates for subsequent partnership or clinical development.

Platform for screening and developing small molecule ligands that modulate orphan nuclear receptors, a class of transcription factors.

Competes with other biotechs pursuing novel oncology and immunology targets, and with large pharma companies with extensive IBD and oncology portfolios. Differentiation lies in exclusive focus on pharmacologically modulating specific orphan nuclear receptors, a niche but unproven therapeutic approach.